People · Operator

Alexander Hafez

Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology

2
Companies
4
Filings
$13.5M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Circular Genomics Inc.BiotechnologySeries A$12.6M$54.6M2021
EquiSeq Inc.BiotechnologyPre-Seed$892K$36.5M2019
Operator network

Alexander Hafez at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

David Blivin · 14 companies · 1 sharedDavid BlivinWaneta Tuttle · 6 companies · 1 sharedWaneta TuttleJoseph Cook III · 4 companies · 1 sharedJoseph Cook IIICathy Petti · 2 companies · 1 sharedCathy PettiBlivin David · 1 companies · 1 sharedBlivin DavidFortunado Rocca · 1 companies · 1 sharedFortunado RoccaKosmas Karadimitriou · 1 companies · 1 sharedKosmas Karadimitr…Nikolaos Mellios · 1 companies · 1 sharedNikolaos MelliosPaul Sargeant · 1 companies · 1 sharedPaul SargeantStephen McKernan · 1 companies · 1 sharedStephen McKernanAlexandra Palmer · 1 companies · 1 sharedAlexandra PalmerHeather Sinclair · 1 companies · 1 sharedHeather SinclairPatrick Jordan · 1 companies · 1 sharedPatrick JordanPaul Szauter · 1 companies · 1 sharedPaul SzauterCircular Genomics Inc. · $12.6M raisedCircular Genomics Inc.EquiSeq Inc. · $0.9M raisedEquiSeq Inc.Alexander HafezAH
Alexander Hafez Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Alexander Hafez on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
David Blivin114
Waneta Tuttle16
Joseph Cook III14
Cathy Petti12
Paul Sargeant11
Nikolaos Mellios11
Stephen McKernan11
Fortunado Rocca11
Blivin David11
Kosmas Karadimitriou11
Paul Szauter11
Patrick Jordan11
Heather Sinclair11
Alexandra Palmer11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.